NorrDia today announced the successful completion of its acquisition of Mozarc’s Global Adult Acute and Chronic Businesses, comprising the former Bellco and Soludia businesses. The transaction further strengthens NorrDia’s position as a global leader in blood purification. It provides the company with a comprehensive portfolio of products and therapies to address the needs of patients across the large and growing acute and chronic blood purification markets.
“Today marks a pivotal milestone for our organization as we warmly welcome Bellco’s talented teams, dedicated partners, and global customer base to the NorrDia family,” said Leo Ling, CEO of NorrDia. “By completing this acquisition, we bring together decades of specialized clinical expertise with innovative, full-spectrum blood purification technologies. Our combined capabilities establish an independent, end-to-end offering spanning equipment, consumables, and fluids, all focused on improving the quality of care for patients requiring acute and chronic blood purification therapies worldwide.”
Today is not about starting over. It is about the start of our journey building on what has been achieved by both companies and creating a stronger platform moving forward.
As our teams come together, our focus is on ensuring continuity for our customers and partners while combining our strengths to support healthcare professionals with reliable, high-quality therapies for renal patients worldwide.
Together, we will build on Bellco’s strong heritage and NorrDia’s capabilities to help shape the future of renal care.
All for the patient. All for our customers. A commitment upheld for decades — our journey continues, together.